Management of Sustained Tachycardia in MASH Cirrhosis

Initial Assessment and Hemodynamic Evaluation

In patients with MASH cirrhosis presenting with sustained tachycardia, immediately assess for underlying precipitants and circulatory dysfunction patterns before initiating treatment, as tachycardia likely represents a compensatory response to hyperdynamic circulation or decompensation, according to the American College of Gastroenterology 1.
Perform bedside echocardiography to distinguish between hypovolemic, vasodilatory, and cardiogenic shock patterns, evaluating left and right ventricular function, inferior vena cava for volume status, and stroke volume variation to determine fluid responsiveness, as recommended by the American College of Cardiology 1.
Decompensated cirrhosis typically presents with hyperdynamic circulation characterized by high cardiac output and low systemic vascular resistance, where tachycardia is a compensatory mechanism, as stated by the European Association for the Study of the Liver 1.

Target a mean arterial pressure (MAP) of 65 mmHg as the primary goal, not heart rate reduction, according to the American College of Gastroenterology 1, 2.
Use balanced crystalloids (Ringer's lactate) as first-line for fluid resuscitation if hypovolemia is suspected, as balanced crystalloids are associated with lower mortality compared to normal saline in critically ill patients, as recommended by the Society of Critical Care Medicine 1.

Administer albumin 20% in specific cirrhosis-related scenarios, such as sepsis-induced hypotension, large volume paracentesis, or suspected hepatorenal syndrome, as recommended by the American Association for the Study of Liver Diseases 1, 2.

Initiate norepinephrine as the first-line vasopressor if hypotension persists despite adequate volume resuscitation, with concurrent ongoing fluid management, according to the American College of Cardiology 1, 2.

Do not use beta-blockers for rate control in this setting, as they may compromise renal function and hemodynamic stability in advanced decompensation, as stated by the American College of Gastroenterology 2.
Avoid ACE inhibitors and angiotensin antagonists, as they aggravate hypotension and have not been clinically useful in cirrhosis, according to the European Association for the Study of the Liver 1.

Monitor complete blood count, comprehensive metabolic panel, liver function tests, daily weight, vital signs, mental status, intake/output, and volume status at least twice weekly initially, then weekly once stable, as recommended by the American Association for the Study of Liver Diseases 2.

Refer immediately for liver transplant evaluation if this represents new decompensation, as median survival with decompensated cirrhosis is approximately 1 year without transplantation, according to the American College of Gastroenterology 2.